2.1 USD
-0.02 (-0.71%)
2.0449 USD
-0.06 (-2.62%)
Taking everything into account, AYTU scores 2 out of 10 in our fundamental rating. AYTU was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AYTU have multiple concerns. AYTU is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
AYTU had negative earnings in the past year.
AYTU had a negative operating cash flow in the past year.
AYTU had negative earnings in each of the past 5 years.
AYTU had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AYTU has a better Return On Assets (-10.46%) than 65.63% of its industry peers.
The Return On Equity of AYTU (-56.41%) is comparable to the rest of the industry.
With a decent Return On Invested Capital value of 1.26%, AYTU is doing good in the industry, outperforming 77.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.46% | ||
| ROE | -56.41% | ||
| ROIC | 1.26% |
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AYTU has a Operating Margin of 1.85%. This is in the better half of the industry: AYTU outperforms 77.08% of its industry peers.
AYTU has a Gross Margin of 67.56%. This is in the better half of the industry: AYTU outperforms 75.52% of its industry peers.
In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.85% | ||
| PM (TTM) | N/A | ||
| GM | 67.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
2. Health
2.1 Basic Checks
AYTU has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for AYTU has been increased compared to 1 year ago.
AYTU has more shares outstanding than it did 5 years ago.
AYTU has a worse debt/assets ratio than last year.
2.2 Solvency
AYTU has an Altman-Z score of -2.91. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
AYTU has a Altman-Z score of -2.91. This is comparable to the rest of the industry: AYTU outperforms 42.71% of its industry peers.
A Debt/Equity ratio of 1.09 is on the high side and indicates that AYTU has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.09, AYTU is doing worse than 71.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.91 |
ROIC/WACC0.1
WACC12.17%
2.3 Liquidity
AYTU has a Current Ratio of 1.23. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of AYTU (1.23) is worse than 79.69% of its industry peers.
A Quick Ratio of 1.08 indicates that AYTU should not have too much problems paying its short term obligations.
AYTU has a Quick ratio of 1.08. This is in the lower half of the industry: AYTU underperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
The earnings per share for AYTU have decreased strongly by -193.62% in the last year.
The Revenue for AYTU has decreased by -15.61% in the past year. This is quite bad
AYTU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.19% yearly.
EPS 1Y (TTM)-193.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.27%
Revenue 1Y (TTM)-15.61%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-14.38%
3.2 Future
Based on estimates for the next years, AYTU will show a very strong growth in Earnings Per Share. The EPS will grow by 36.95% on average per year.
AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.87% yearly.
EPS Next Y32.27%
EPS Next 2Y35.3%
EPS Next 3Y36.95%
EPS Next 5YN/A
Revenue Next Year-19.22%
Revenue Next 2Y2.13%
Revenue Next 3Y10.25%
Revenue Next 5Y14.87%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
Also next year AYTU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AYTU is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.08 |
4.3 Compensation for Growth
AYTU's earnings are expected to grow with 36.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.3%
EPS Next 3Y36.95%
5. Dividend
5.1 Amount
AYTU does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.1
-0.02 (-0.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.09%
Inst Owner Change6.48%
Ins Owners8.18%
Ins Owner Change1.64%
Market Cap20.81M
Revenue(TTM)63.70M
Net Income(TTM)-13.07M
Analysts82.22
Price Target9.35 (345.24%)
Short Float %5.56%
Short Ratio2.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3758.63%
Min EPS beat(2)-7706.78%
Max EPS beat(2)189.51%
EPS beat(4)3
Avg EPS beat(4)-1821.8%
Min EPS beat(4)-7706.78%
Max EPS beat(4)221.11%
EPS beat(8)6
Avg EPS beat(8)-879.29%
EPS beat(12)8
Avg EPS beat(12)-891.94%
EPS beat(16)10
Avg EPS beat(16)-685.51%
Revenue beat(2)1
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-17.2%
Max Revenue beat(2)9.83%
Revenue beat(4)3
Avg Revenue beat(4)6.63%
Min Revenue beat(4)-17.2%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)5.43%
Revenue beat(12)7
Avg Revenue beat(12)0.63%
Revenue beat(16)9
Avg Revenue beat(16)0.23%
PT rev (1m)0%
PT rev (3m)-5.17%
EPS NQ rev (1m)2.08%
EPS NQ rev (3m)-67.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-97.65%
Revenue NQ rev (1m)-2.01%
Revenue NQ rev (3m)-23.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 0.08 |
EPS(TTM)-2.76
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS6.43
BVpS2.34
TBVpS-1.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.46% | ||
| ROE | -56.41% | ||
| ROCE | 2% | ||
| ROIC | 1.26% | ||
| ROICexc | 2.26% | ||
| ROICexgc | N/A | ||
| OM | 1.85% | ||
| PM (TTM) | N/A | ||
| GM | 67.56% | ||
| FCFM | N/A |
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
F-Score3
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 65.05% | ||
| Cap/Sales | 4.85% | ||
| Interest Coverage | 0.4 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | -2.91 |
F-Score3
WACC12.17%
ROIC/WACC0.1
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-193.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.27%
EPS Next Y32.27%
EPS Next 2Y35.3%
EPS Next 3Y36.95%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.61%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-14.38%
Revenue Next Year-19.22%
Revenue Next 2Y2.13%
Revenue Next 3Y10.25%
Revenue Next 5Y14.87%
EBIT growth 1Y177.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year137.32%
EBIT Next 3Y85.15%
EBIT Next 5YN/A
FCF growth 1Y-216.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.83%
OCF growth 3YN/A
OCF growth 5YN/A
AYTU BIOPHARMA INC / AYTU FAQ
Can you provide the ChartMill fundamental rating for AYTU BIOPHARMA INC?
ChartMill assigns a fundamental rating of 2 / 10 to AYTU.
What is the valuation status of AYTU BIOPHARMA INC (AYTU) stock?
ChartMill assigns a valuation rating of 2 / 10 to AYTU BIOPHARMA INC (AYTU). This can be considered as Overvalued.
Can you provide the profitability details for AYTU BIOPHARMA INC?
AYTU BIOPHARMA INC (AYTU) has a profitability rating of 3 / 10.
Can you provide the financial health for AYTU stock?
The financial health rating of AYTU BIOPHARMA INC (AYTU) is 1 / 10.